智飛生物(300122.SZ):23價肺炎球菌多糖疫苗獲批上市
格隆匯9月1日丨智飛生物(300122.SZ)公佈,公司近日獲悉由公司全資子公司北京智飛綠竹生物製藥有限公司研發的23價肺炎球菌多糖疫苗獲得國家藥品監督管理局出具的《藥品註冊證書》。
肺炎鏈球菌是導致各年齡組人羣社區獲得性肺炎的最重要病原菌,同時也是引起中耳炎、肺炎、腦膜炎和菌血症的主要病原菌。世界衞生組織將肺炎球菌疾病列為需“極高度優先”使用疫苗預防的疾病。23價肺炎球菌多糖疫苗適用於2歲及以上兒童、成人預防肺炎球菌引起的感染性疾病,是目前國內外預防肺炎球菌感染的最主要產品之一。
此次23價肺炎球菌多糖疫苗獲得《藥品註冊證書》是公司自主研發實力的體現,有利於貫徹“技術&市場”雙輪驅動的發展模式,促進公司實現長期可持續發展。
目前國內外已有多款23價肺炎球菌多糖疫苗上市。截至公吿披露日,經查詢國家藥品監督管理局網站,國內共有五款同類產品獲批使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.